30DEC

Libyan International Conference for Health Sciences

The First Libyan International Conference for Health Sciences (2024): Open University, Tripoli, Libya
Mediterranean Journal of Pharmacy and Pharmaceutical Sciences
https://ppj.org.ly/article/doi/10.5281/zenodo.7115181

Mediterranean Journal of Pharmacy and Pharmaceutical Sciences

Original article

Clinical pharmacokinetics: perceptions of Libyan hospital pharmacists about how it was taught and how it is applied

Mawada S. Gajam, Saadoun O. Elmezughi, Abdurrauf M. Gusbi, Abdurrahim A. Elouzi, Ebtisam A. Benomran, Mahmud H. Arhima

Downloads: 0
Views: 31

Abstract

The application of clinical pharmacokinetics is the responsibility of all pharmacists providing pharmaceutical care. An appropriately applied clinical pharmacokinetic is expected to result in improved patient outcomes: decreased mortality, reduced length of treatment, reduced length of hospital stays and cost-savings. Data on the extent of pharmacokinetic application in Libyan hospitals remain scarce but available subjective evidence suggests that services related to clinical pharmacokinetics are mostly provided and performed by professionals other than clinical pharmacists. To explore the training background and perceptions of pharmacists on the pharmacokinetic course contents they received during their undergraduate pharmacy programs. Also, to determine the attitudes and barriers experienced by the pharmacists when applying pharmacokinetic principles in their current practice. This is a cross-sectional, descriptive study that was conducted between July 2018 and November 2019 using a self-administered survey. The study targeted hospital pharmacists practicing in different hospitals in Libya. A total of 104 pharmacists completed the questionnaire and submitted it back. The majority of participants learned pharmacokinetic courses as a mandatory course during undergraduate courses 81.0% with 37.0% selecting that course was taught as a separate course or courses. Around 80.0% of the participants agreed or strongly agreed that pharmacokinetic courses received in undergraduate studies are useful in pharmacy practice with over 75.0% of the participants agreeing or strongly agreeing on the relevance of those courses to their current clinical practice. About 40.0% of the participants described their current skills in allowing optimal patient care as being better. Different barriers were highlighted by the participants to allow sufficient clinical pharmacokinetic practice including lack of sufficient information, and lack of awareness of pharmacists’ role and skills in applying clinical pharmacokinetic by other pharmacists and by other health care providers. Thus, this study shows that most practicing pharmacists showed a positive attitude to current pharmacokinetic practice and to the impact of their undergraduate studies on their successful practice. However, they have clearly addressed the room for improvement.

Keywords

Clinical pharmacokinetic, perception, pharmacist, Libya, undergraduate program

References

  1. American Society of Health-System Pharmacists (1998) ASHP statement on the pharmacist’s role in clinical pharmacokinetic monitoring. American Journal of Hospital Pharmacy. 55 (16): 1726-1727. doi: 10.1093/ajhp/ 55.16.1726
  2. Dhillon S, Gill K (2006) Basic pharmacokinetics. Clinical Pharmacokinetics. Pharmaceutical press. London, UK. ISBN: 978 0 85369 571 4.
  3. Ratanajamit C, Kaewpiba P, Setthawacharavanich S, Faroongsarng D (2009) Effect of pharmacist participation in the health care team on therapeutic drug monitoring utilization for antiepileptic drugs. Journal of Medical Association of Thailand. 92 (11): 1500-1507. PMID: 19938743.
  4. Cies JJ, Varlotta L (2013) Clinical pharmacist impact on care, length of stay, and cost in pediatric cystic fibrosis (CF) patients. Pediatric Pulmonology. 48 (12): 1190-1194. doi: 10.1002/ppul.22745
  5. Ensom MH, Davis GA, Cropp CD, Ensom RJ (1998) Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes? Clinical Pharmacokinetics. 34 (4): 265-279. doi: 10.2165/00003088-199834040-00001
  6. Touw DJ, Neef C, Thomson AH, Vinks AA (2005) Cost-effectiveness of therapeutic drug monitoring: a systematic review. Therapeutic Drug Monitoring. 27 (1): 10-17. doi: 10.1097/00007691-200502000-00004
  7. Vozeh S (1987) Cost-effectiveness of therapeutic drug monitoring. Clinical Pharmacokinetics. 13 (3): 131-140. doi: 10.2165/00003088-198713030-00001
  8. Murphy R, Chionglo M, Dupuis LL (2007) Impact of a pharmacist initiated therapeutic drug monitoring consult service for children treated with gentamicin. Canadian Journal of Hospital Pharmacy. 60 (3): 162-168.  doi: 10.4212/cjhp.v60i3.170
  9. Shenfield GM (1998) Therapeutic drug monitoring beyond 2000. British Journal of Clinical Pharmacology. 46 (2): 93-94. doi: 10.1046/j.1365-2125.1998.00771.x
  10. Hurley SF, Dziukas LJ, McNeil JJ, Brignell MJ (1986) A randomized controlled clinical trial of pharmacokinetic theophylline dosing. The American Review of Respiratory Disease. 134 (6): 1219-1224. doi: 10.1164/arrd. 1986.134.5.1219
  11. Karcirova I, Grundmann M (2017) TDM of aminoglycoside antibiotics and vancomycin as an indicator of the quality of medical care: results of the 7-years monitoring. Clinical Therapeutics. 39 (8): e83. doi: 10.1016/ j.clinthera.2017.05.256
  12. Lehmann CR, Leonard RG (1982) Effect of theophylline pharmacokinetic monitoring service on cost and quality of care. American Journal of Hospital Pharmacy. 39 (10): 1656-1662.  doi: 10.1093/ajhp/39.10.1656
  13. Hamzah A, Ab-Rahman AF (2008) Evaluation of blood sampling times and indications for therapeutic drug monitoring services. Malaysian Journal of Pharmaceutical Sciences. 6 (1): 1-11. doi: Nil.
  14. Jones D (2009) Therapeutic drug monitoring: a vital pharmacy role. British Journal of Clinical Pharmacy. (3/1/2015). doi: Nil.
  15. Kheir N, Awaisu A, Gad H, Elazzay S, Jibril F, Gajam M (2015) Clinical pharmacokinetics: perceptions of hospital pharmacists in Qatar about how it was taught and how it is applied. International Journal of Clinical Pharmacy. 37 (6): 1180-1187. doi: 10.1007/s11096-015-0183-3
  16. Kheir N, Fahey M (2011) Pharmacy practice in Qatar: challenges and opportunities. Southern of Medical Review. 4 (2): 92-96. doi: 10.5655/smr.v4i2.1007
  17. Zaidan M, Singh R, Wazaify M, Tahaineh L (2011) Physicians’ perceptions, expectations, and experience with pharmacists at Hamad Medical Corporation in Qatar. Journal of Multidisciplinary Healthcare. 4: 85-90. doi: 10.2147/JMDH.S14326
  18. Murphy JE, Slack MK, Campbell S (1996) National survey of hospital based pharmacokinetic services. American Journal of Health System Pharmacy. 53 (23): 2840-2847. doi: 10.1093/ajhp/53.23.2840
  19. Boynton PM, Greenhalgh T (2004) Selecting, designing, and developing your questionnaire. British Medical Journal. 328 (7451): 1312-1315. doi: 10.1136/bmj.328.7451.1312
  20. Saw SM, Ng TP (2001) The design and assessment of questionnaires in clinical research. Singapore Medical Journal. 42 (3): 131-135. PMID: 11405568.
  21. Aldaz A, Ferriols R, Aumente D, Calvo MV, Farre MR, García B, Marqués R, Mas P, Porta B, Outeda M, Soy D, Grupo PK-gen de la Sociedad Española de Farmacia Hospitalaria (2011) Pharmacokinetic monitoring of antiepileptic drugs. Farmacia Hospitalaria. 35 (6): 326-339. doi: 10.1016/j.farma.2010.10.005
  22. Naik GS, Kodagali R, Mathew BS, Thomas M, Prabha R, Mathew V, et al. (2015) Therapeutic drug monitoring of levetiracetam and lamotrigine: is there a need? Therapeutic Drug Monitoring. 37 (4): 437-444. doi: 10.1097/FTD.0000000000000158
  23. Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, Leppik IE, Tomson T, Percuca E (2008) Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic. Epilepsia. 49 (7): 1239-1276. doi: 10.1111/j.1528-1167.2008.01561.x
  24. Stepanova D, Beran RG (2015) The benefits of antiepileptic drug (AED) blood level monitoring to complement clinical management of people with epilepsy. Epilepsy Behavior. 42: 7-9. doi: 10.1016/j.yebeh.2014.09.069
  25. Duhme DW, Greenbaltt DJ, Koch-Weser J (1974) Reduction of digoxin toxicity associated with measurement of serum levels. A report from the Boston Collaborative Drug Surveillance Program. Annals of Internal Medicine. 80 (4): 516-519. doi: 10.7326/0003-4819-80-4-516
  26. Horn JR, Christensen DB, de Blaquiere PA (1985) Evaluation of a digoxin pharmacokinetic monitoring service in a community hospital. Drug Intelligence and Clinical Pharmacy. 19 (1): 45-52. doi: 10.1177/10600280 8501900112
  27. Spruill WJ, Wade WE (2003) Curricular and content survey of clinical pharmacokinetics courses. American Journal of Pharmaceutical Education. 67 (2): 1-11. doi: 10.5688/AJ670247
  28. Brackett CC, Reuning RH (1999) Teaching pharmacokinetics using a student-centered, modified mastery-based approach. American Journal of Pharmaceutical Education. 63: 272-277. doi: Nil.
  29. Kruger J, Dunning D (1999) Unskilled and unaware of it: how difficulties in recognizing one’s own incompetence led to inflated self-assessments. Journal of Personality and Social Psychology. 77 (6): 1121-1134. doi. 10.1037/0022-3514.77.6.1121
  30. Hughes GJ, Lee R, Sideras V (2018) Design and delivery of clinical pharmacokinetics in colleges and schools of pharmacy. American Journal of Pharmaceutical Education. 82 (9): 6430. doi: 10.5688/ajpe6430
  31. Azzopardi LM, Serracino-Inglott A (2020) Clinical pharmacy education and practice evolvement in Malta. Journal of the American College of Clinical Pharmacy. 3(5): 973-979. doi.10.1002/jac5.1280

Submitted date:
08/14/2022

Reviewed date:
08/31/2022

Accepted date:
09/10/2022

Publication date:
11/07/2024

672d3967a9539543717d9772 medjpps Articles
Links & Downloads

Mediterr J Pharm Pharm Sci

Share this page
Page Sections